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C4b Binding Protein (C4BP) is a major fluid phase inhibitor of the classical and lectin
pathways of the complement system. Complement inhibition is achieved by binding to
and restricting the role of activated complement component C4b. C4BP functions as a
co-factor for factor I in proteolytic inactivation of both soluble and cell surface-bound C4b,
thus restricting the formation of the C3-convertase, C4b2a. C4BP also accelerates the
natural decay/dissociation of the C3 convertase. This makes C4BP a prime target for
exploitation by pathogens to escape complement attack, as seen in Streptococcus
pyogenes or Flavivirus. Here, we examined whether C4BP can act on its own in a
complement independent manner, against pathogens. C4BP bound H1N1 and H3N2
subtypes of Influenza A Virus (IAV) most likely via multiple sites in Complement Control
Protein (CCP) 1-2, 4-5, and 7-8 domains of its a-chain. In addition, C4BP CCP1-2 bound
H3N2 better than H1N1. C4BP bound three IAV envelope proteins: Haemagglutinin (~70
kDa), Neuraminidase (~55 kDa), and Matrix protein 1 (~25kDa). C4BP suppressed H1N1
subtype infection into the lung epithelial cell line, A549, while it promoted infection by
H3N2 subtype. C4BP restricted viral entry for H1N1 but had the opposite effect on H3N2,
as evident from experiments using pseudo-typed viral particles. C4BP downregulated
mRNA levels of pro-inflammatory IFN-a, IL-12, and NFkB in the case of H1N1, while it
promoted a pro-inflammatory immune response by upregulating IFN- a, TNF-a, RANTES,
and IL-6 in the case of H3N2. We conclude that C4BP differentially modulates the efficacy
of IAV entry, and hence, replication in a target cell in a strain-dependent manner, and acts
as an entry inhibitor for H1N1. Thus, CCP containing complement proteins such as factor
H and C4BP may have additional defense roles against IAV that do not rely on the
regulation of complement activation.
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The complement system plays a crucial role in our early response
against invading pathogens, including viruses. The complement
system is activated via three pathways—Classical, Alternative,
and Lectin. The classical pathway is activated through the
binding of C1q to IgG or IgM-containing immune complexes
or other non-immunoglobulin targets. Non-self-carbohydrate
targets are recognized by Mannose Binding Lectin (MBL) or
ficolins triggering the lectin pathway. The activation of classical
or lectin pathways leads to the cleavage of C4 and C2, yielding C3
convertase (C4b2a), which then cleaves C3 to form C3b. For the
alternative pathway, C3 is spontaneously hydrolyzed to a C3b-
like form [C3(H2O)] due to the hydrolysis of the internal
thioester bond. The C3(H2O) binds to Factor B, which enables
Factor D to cleave Factor B to Bb. This then forms C3(H2O)Bb,
which is homologous to the C3 convertase, C4b2a. C3(H2O)Bb
then cleaves C3 to C3b, and C3b can bind covalently to target
surfaces, on which it forms more convertase, C3bBb. The
binding of the C3b to C4b2a or C3bBb converts them into
classical or alternative pathway C5 Convertases, respectively. The
subsequent cleavage of C5 by the C5 convertases initiates the
formation of the Membrane Attack Complex (C5b-C9). This
complex binds to the microbial surface and can cause lysis of
lipid bilayer membranes (1).
The complement system is kept in check by various regulatory
proteins to prevent runaway reactions leading to unnecessary
inflammation and death of healthy cells. One such humoral
regulator is C4b Binding Protein (C4BP). C4BP, like other
complement regulators Factor H, CR1, CD46, CD55, and the
Factor H-related family, is encoded by a gene present in the long
arm of chromosome 1 and is synthesized and secreted mainly by
hepatocytes (2). The normal range of C4BP in human plasma is
estimated to be approximately 150–300 µg/ml (3). C4BP regulates
complement activation by controlling C4b mediated reactions (4).
C4BP, a 570 kDa glycoprotein, functions as a primary fluid phase
regulator of the classical and lectin pathways (5). It consists of seven
identical 70 kDa a-chains and a 45 kDa b-chain that are linked at
their carboxy-terminal ends by short amphipathic helices further
stabilized bydisulfide bonds (6). Thea- chains andb-chain contain
eight and three ComplementControl Protein (CCP) domains, each
of ~60 amino acids, respectively. The polymerization of the
polypeptide chains of C4BP occurs via a short C-terminal region,
downstream of CCP8 (7). Each molecule of C4BP can bind only
fourmolecules of C4b due to steric hindrance, although each of the
sevena- chains has a C4b binding site (8). The binding site for C4b
has been localized to CCP1-3, especially within a cluster of
positively charged residues at the interface of CCP1 and CCP2 (9,
10). C4BP has been shown to inhibit the formation of C3 and C5
convertases, accelerate the decay of the convertases, and act as a co-
factor for Factor I which cleaves and thereby inactivates fluid phase
and cell-boundC4b (9–12). The co-factor activity of the protein has
been linked to CCP1-4 (13).
Consistent with its role as an immunomodulator, C4BP also
engages with pathogens. Flaviviruses limit complement
activation by binding C4BP through their NS1 protein: the
bound C4BP inactivates soluble or membrane-bound C4b (5).Frontiers in Immunology | www.frontiersin.org 2Streptococcus pyogenes uses its Protein H to recruit C4BP in
order to facilitate the invasion of endothelial cells and reduce the
chances of its opsonization by bound C3b, or attack by the MAC
(14). C4BP probably is also recruited by other pathogens to limit
C3 opsonization, MAC mediated lysis, and immune system
activation by C3a/C5a (15).
C4BPhas been reported to have properties that are independent
of its involvement in complement regulation. For example, C4BP
is known to facilitate the uptake of adenoviruses by hepatocytes via
its interaction with heparin-sulfate proteoglycans found on cell
surfaces (16). C4BP induces proliferation and activation of B
lymphocytes by binding with CD40 (17). Interaction between
CD40, CD154, and C4BP inhibits apoptosis in epithelial cells.
C4BP has also been implicated in inhibiting DNA release from
necrotic cells in conjunction with Protein S by binding to
phosphatidylserine (18–20). C4BP also have an association with
the clotting system as the b-chain binds the vitamin K-dependent
anticoagulant protein S (21).
In this study, we investigated potential complement-
independent defense functions of C4BP against Influenza A
Virus (IAV). Influenza virus causes an upper respiratory tract
infection affecting the nose, throat, bronchi, and sometimes the
lungs. Of the three genera of Influenza virus that belong to the
Orthomyxoviridae family, IAV is known to cause pandemics.
IAV causes Influenza in birds and a few species of mammals,
including humans and pigs. Its wide host range has led to
pandemics such as the 1918 Spanish flu, which caused 20–50
million deaths (22). It has several subtypes based on variants of
two proteins on the surface of the viral envelope. These proteins
are Hemagglutinin (HA), which causes RBCs to agglutinate, and
Neuraminidase (NA), which breaks the glycoside bonds of
neuraminic acid (23). Currently, there are 18 known variations
of HA, and 11 known variations of NA, theoretically allowing
198 different combinations (24, 25). Some of the well-known
combinations are H1N1 that caused the 1918 Spanish flu, 1977
Russian flu, and 2009 flu Pandemic, H3N2 that caused the 1968
Hong Kong flu and H2N2 that caused 1957 Asian flu (26).
Human infection by IAV is achieved through oral or nasal
cavities, where the viral HA binds sialic acids in order to attach to
lung epithelial cells (27). The HA protein of the human-infecting
IAV has increased specificity for a-2,6-linked sialic acid (28). Sialic
acid, a nine-carbon acidic monosaccharide, is commonly found
with a-2,6-linkages and a few a-2,3-linkages on human tracheal
epithelial cells (29). Once bound to the cell surface, the viral particle
undergoes receptor-mediated endocytosis. We show here that IAV
interacts with the a chain of C4BP mainly via CCP domains 4–5,
CCP domains 7–8, and to a lesser extent CCP domains 1–2. C4BP
acts as anentry inhibitor forH1N1subtypewhenchallengedagainst
A549 (lung epithelial) cells and suppresses the pro-inflammatory
cytokine storm induced by IAV.MATERIALS AND METHODS
Purification of Native C4BP
C4BP was isolated from human plasma as described previously
(30). Briefly, C4BP was purified from neutral euglobulinJanuary 2021 | Volume 11 | Article 585361
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equilibrated in 5 mM EDTA/25 mM potassium phosphate
buffer, pH 7.0. The column was washed in the same buffer and
then bound protein was eluted by a linear gradient of NaCl from
0 to 2 M; C4BP was eluted at 0.8 M NaCl. The peak fractions
were run on 12% w/v acrylamide SDS-PAGE to assess purity and
adjusted to 1 mg/ml concentration. The immunoreactivity of this
plasma purified C4BP was assessed via western blotting.
Expression and Purification of
Recombinant Complement Control Protein
Deletants of C4BP a-Chain
Recombinant a-chain of C4BP (rC4BP) and C4BP a-chain CCP
deletants (Table 1) were provided by Prof. Anna Blom, Lund
University, Malmo, Sweden. Briefly, CCP deletant constructs
were expressed in Human Embryonic Kidney (HEK) 293 cells
(ATCC number 1573-CRL). The transfected cells were selected
using neomycin analogue G418 (400 mg/ml), and colonies
expressing the highest amount of CCP deletants were assessed
by immunoblotting. The medium collected from transfected cells
was subjected to the purification of CCP deletants using mAb
104 affinity columns (directed against CCP1) or mAb 67
(directed against CCP4) coupled to Affi-Gel 10 (2.6 × 12 cm
column; Bio-Rad) (10). The recombinant CCP deletants were
eluted using 3M guanidinium chloride, and the purified fractions
were subjected to SDS-PAGE with 12% w/v acrylamide/
bisacrylamide (10).
Preparation of Viral Stocks and Titration
A/England/2009 (H1N1) was a gift from Wendy Barclay,
Department of Infectious Disease, Imperial College London,
and the A/HK/99 (H3N2) was a gift from Leo Poon, Division
of Public Health Laboratory Sciences, University of Hong Kong.Frontiers in Immunology | www.frontiersin.org 3Madin Darby Canine Kidney (MDCK) (ATCC® CCL-34™)
cells, grown to 70% confluence in a 175 cm2 flask (Fisher
Scientific) in growth medium (DMEMF/12 with GlutaMAX™
Supplement (Gibco), + 10% v/v Heat Inactivated Fetal Bovine
Serum (FBS) (Gibco) + 1% v/v Penicillin-Streptomycin (PS)
(Gibco) at 37°C under 5% v/v CO2, were washed with PBS
twice to remove any residual serum-complemented DMEM
media. H1N1 and H3N2 IAV subtypes were added to the
MDCK cells diluted in serum-free DMEM (Gibco) and allowed
to incubate for 1 h at 37°C. The medium was removed, and cells
were washed with Phosphate-buffered saline (PBS) (0.01M
sodium phosphate, 0.0027M KCl, and 0.137M NaCl, pH 7.4 at
25°C) (Fisher Bioreagents) to remove any unbound viruses. The
cells were then incubated for 3 days at 37°C in the infectionmedium
[DMEM + 1% penicillin/streptomycin + 0.3% w/v bovine serum
albumin (BSA) + 1 µg/ml of l-1-Tosylamide-2-phenylethyl
chloromethyl ketone (TPCK)-Trypsin] (Sigma-Aldrich)]. TPCK
treated Trypsin mediates the cleavage of HA0 into two subunits
HA1 and HA2, which are required to make HA fusion competent.
After the incubation, the medium was collected and centrifuged in
sealed containers at 3,000 × g at 4°C for 15 min. The supernatant
containing the viral particles was harvested, and the titer of the
particles was determined via 50% Tissue culture Infective Dose
(TCID50) Assay. Purified virus stocks were serially diluted in a 96-
well plate up to 10−7-fold with ½ log10 increments. 1 × 10
5 MDCK
cells were added to eachwell and incubated for 3 days at 37°Cunder
5% v/v CO2. UninfectedMDCK cells were used as negative control.
The titter of the virus was determined to be 1 × 106 PFU/ml by
TCID50 using the Reed–Muench method (31).
Production of Pseudo-Typed Lentiviral
Particles
Pseudo-typed Lentiviral Particles were produced as previously
described by Murugaiah et al., 2020 (32). Briefly, HEK 293T cells
were cultured in RPMI 1640 (Gibco), supplemented with 10%
v/v heat inactivated Fetal Bovine Serum (FBS) (Gibco), 1% v/v
Penicillin-Streptomycin (Gibco) at 37°C under 5% v/v CO2. Cells
were co-transfected using 20 µg of the Envelope Protein-Coding
plasmids that yield the viral envelope proteins [H1 and N1 or H3
and N2 or Vesicular Stomatitis Virus G protein (VSV-G)], an
HIV-backbone containing a modified pro-viral HIV-1 genome
with the env deleted and designed to express the firefly luciferase
reporter and second or third-generation lentiviral vector
packaging plasmid (Table 2). The culture supernatant was
collected after 48 h (by centrifugation at 1,500 × g for 5 min).TABLE 1 | C4BP deletants used in this study.












pcDNA3.1-swineH1-flag (H1 from swine H1N1 A/California/04/
09) (Codon optimized H1 (Genecust))
pcDNA-H3 [H3 from A/Denmark/70/03/(H3N2)]
(Codon optimized H3 (Geneart))
pCMV-VSV-G (Addgene
plasmid # 8454)
pcDNA3.1-swine N1-flag (N1 from swine H1N1 A/California/04/
09) (Codon optimized N1 (Genecust))
pI.18-N2 (N2 from human H3N2 A/Texas/50/
2012)
Backbone Plasmid pHIV-Luciferase (Addgene plasmid # 21375)
Packaging Plasmid psPAX2 (Addgene plasmid # 12260)January 2021 | Volume 11 | Article 585361
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mM Tris–HCl pH 7.5, 200 mM NaCl, 5 mM EDTA, 0.1% v/v
Triton X-100) and were centrifuged at 1,500 × g for 5 min to
remove cell debris. The total lysate and supernatant were filtered
with a 22 µm filter. The pseudo-typed lentiviral particles were
harvested by centrifuging the filtered cell lysate and the
supernatant at 5,000 × g for 10 min at 4°C in a closed
container. The lentiviral particles in the supernatant were then
concentrated by ultracentrifugation at 25,000 × g for 3 h at 4°C
(33). The pseudo-typed lentiviral particles produced were
characterized by western blotting (32).
ELISA to Detect C4BP-Virus Interaction
Microtiter wells of 96-well plates (Nunc # 4912) were coated
(4°C, overnight) with the virus [100 µl of H1N1 or H3N2
subtypes (1,000 PFU/ml)] in carbonate-bicarbonate buffer, pH
9.6 (Sigma # c3041). Other wells were coated with 100 µl/well of
C4BP, a-chain CCP mutants, at 5, 2.5, 1.25 µg/ml in the same
buffer. In another experiment, 5 µg/ml of rC4BP was similarly
coated. Unbound proteins or viruses were removed by washing
the wells three times with PBST Buffer (PBS + 0.05% Tween 20)
(Fisher Scientific). The wells were then blocked using 2% w/v
BSA in PBS (Fisher Scientific) for 2 h at 37°C and washed three
times using PBST. Decreasing concentrations of C4BP (5, 2.5,
1.25 µg/ml) were added to the wells in which the virus was coated
to study its binding to immobilized viral particles. In parallel
experiments, 1,000 PFU/ml of purified H1N1 and H3N2 were
added to the protein-coated wells to study the binding of the
virus to immobilized C4BP or rC4BP. The wells were incubated
for 2 h at 37°C and then washed with PBST to remove any
unbound viruses or protein. VSV-G pseudo-typed lentivirus was
used as a negative control. The wells were probed using
polyclonal rabbit anti-human C4BP (1 mg/ml of purified IgG;
MRC Immunochemistry Unit, Oxford) to detect the virus-bound
C4BP. Monoclonal Anti-Influenza Virus H1 HA, A/California/
04/2009 (H1N1)pdm09, Clone 5C12 (produced in vitro) (BEI-
Resources, NIAID, NIH, USA), Polyclonal Anti-Influenza Virus
H3 HA, A/Hong Kong/1/1968 (H3N2) (antiserum, Goat, NR-
3118) (BEI-Resources, NIAID, NIH, USA), and polyclonal anti-
VSV-G (1 mg/ml of purified IgG; Imperial College London) were
used to detect H1N1, H3N2 and pseudo-typed lentivirus
particles, respectively that were bound to the immobilized
C4BP. All antibodies were used at a dilution of 1:5,000 for 1 h
at 37°C. Unbound antibodies were removed by washing three
times using PBST. Anti-mouse IgG-Horseradish peroxidase
(HRP) (Promega, #W4021), goat anti-rabbit IgG HRP (1:1,000;
Promega # W4011), or Protein A-HRP (Invitrogen) were used as
appropriate at 1:5,000 dilution as secondary antibodies (1 h at
37°C). 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate set
(Biolegend) was used as per the manufacturer’s instruction,
and 1 M sulfuric acid (Fisher Chemical) was used to stop the
reaction. The plate was read at 450 nm using an iMark™
microplate absorbance reader (BioRad).
Western Blot
H1N1 and H3N2 (7.5 × 105 PFU/ml), treated with NuPAGE LDS
Sample Buffer (4X) (Invitrogen™) were subjected to 12% w/vFrontiers in Immunology | www.frontiersin.org 4reducing SDS-PAGE (120 min, 90 V). The proteins were then
transferred to Polyvinylidene fluoride (PVDF) membranes
(Millipore) by electroblotting (320 mA for 2 h) at 4°C. The
membrane was then blocked using 5% w/v skimmed milk in PBS
for 16 h at 4°C.
For far-western blot, the membrane was washed with PBS and
incubated with 5 µg/ml of C4BP for 1 h at room temperature and
another 1 h at 4°C on a rotary shaker. After washing with PBST,
the PVDF membrane was probed using rabbit polyclonal
anti-human C4BP antibody (1mg/ml) (1:1,000; MRC
Immunochemistry Unit, Oxford) for 1 h at room temperature
on a rotary shaker. Following three washes with PBST, the
membrane was probed again with goat anti-rabbit IgG HRP
conjugate (1:1,000; Promega #W4011) for 1 h; the blot was
developed using 3,3′-diaminobenzidine (DAB) (Sigma) as
a substrate.
For direct western blot for viral proteins, the PVDF
membrane, containing electro-transferred viral proteins, was
incubated with appropriate antibodies: these included
monoclonal anti-IAV H1, polyclonal anti-IAV H3, Monoclonal
anti-IAV Neuraminidase (NA), Clone NA2-1C1 (produced in
vitro) (BEI-Resources, NIAID, NIH, USA), Polyclonal Anti-
Influenza Virus N2 Neuraminidase (NA), A/shorebird/
Delaware/127/1997 (H6N2) (antiserum, Goat) (BEI-Resources,
NIAID, NIH, USA), Monoclonal Anti-Influenza A Virus Non-
structural Protein 1 (NS1), Clone NS1-1A7 (produced in vitro)
(BEI-Resources, NIAID, NIH, USA), or Monoclonal anti-Matrix
protein 1 (M1) antibody (Abcam) as required for 1 h at room
temperature on a rotary shaker. Following three washes with
PBST, the membrane was probed with either anti-mouse HRP or
Protein A-HRP conjugate, as appropriate for 1 h at room
temperature on a rotary shaker. Following three washes with
PBST, the blot was developed using DAB.
A549 Cell Infection Assay
Human alveolar basal epithelial cells derived from an
adenocarcinoma (A549) (ATCC® CCL-185™) (5 × 105) were
cultured for 12 h in each well of a 12-well plate in growth
medium. Post-attachment, the cells were serum starved by
incubating them in serum-free DMEM for 24 h. H1N1 and
H3N2 subtypes (MOI 1) were incubated with C4BP (10, 20, or 40
µg/ml) in PBS for 1 h and added to A549 cells in serum-free
DMEM. After 1 h incubation at 37°C, the medium was removed,
and cells were washed with PBS to remove any unbound IAV.
Infection medium (DMEM + 1% v/v Penicillin-Streptomycin +
0.3% w/v BSA + 1 µg/ml of TPCK-Trypsin) was added to the
cells and incubated for 2 or 6 h. The cells were then harvested by
scraping with a sterile disposable cell scraper and centrifuging at
1,500 × g for 5 min. Total RNAwas extracted using the GenElute™
Mammalian Total RNA Miniprep Kit (Sigma). Contaminating
DNA was removed by treating the RNA samples with DNase I
(Sigma) for 15 min. DNase I was inactivated by heating at 70°C
for 10 min. The quantity and quality of the extracted RNA
were assessed using a Nanodrop 2000 spectrophotometer
(Thermo Fisher) via absorbance at 260 nm and 260:280 nm
ratio. mRNA was converted to cDNA using TaqMan™ High
Capacity RNA to cDNA Kit (Applied Biosystems™). The cDNAJanuary 2021 | Volume 11 | Article 585361
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using a StepOnePlus System (Applied Biosystems™) at 95°C for
5 min, followed by 45 cycles of 95°C for 10 s, 60°C for 10 s,
and 72°C for 10 s. The specificity of the assay was established
by melting-curve analysis. The relative expression (RQ)
was calculated by using C4BP untreated cells infected with
respective viruses as the calibrator. The RQ value was
calculated using the formula: RQ = 2−DDCt. Primers were
generated for specificity using the Primer-BLAST software
(Basic Local Alignment Search Tool) (http://blast.ncbi.nlm.nih.
gov/Blast.cgi) (Table 3).
Luciferase Assay
MDCK cells were seeded in a 96-well plate (1 × 105 cells per well)
and were serum starved. The cells were infected for 24 h in the
infection medium with 50 µl of the H1N1 and H3N2 pseudo-
typed particles that were pre-incubated with C4BP for 1 h, or
pseudo-typed particles that were not treated with C4BP. Post-
infection, luciferase activity in the cells was measured using
Pierce™ Firefly Luc One-Step Glow Assay Kit (Thermo Fisher)
and CLARIOstar Plus Plate Reader (BMG Labtech).
Statistical Analysis
GraphPad Prism 8.0 software was used to create all graphs. Two-
way ANOVA was used to find the statistical significance of the
data generated. Significant values were considered based on *p <
0.1, **p < 0.05, ***p < 0.01, and ****p < 0.001 between treated
and untreated conditions. Error bars show the standard
deviation among the samples.RESULTS
C4BP Directly Binds to Influenza A Virus in
a Dose-Dependent Manner
Native C4BP, purified from plasma, was run on a 12% w/v
reducing SDS-PAGE, which revealed a band corresponding to
a-chain (~70 kDa), and one corresponding to b-chain (~45 kDa)
(Figure 1A). The immunoreactivity of the protein was determined
by performing a western blot with rabbit polyclonal anti-human
C4BP antibodies, which yielded a band corresponding to the a-
chain (~70 kDa) of C4BP. However, the b-chain (~45 kDa) was
barely visible (Figure 1B). Indirect ELISA was then performed to
examine the binding of C4BP to IAV subtypes. Binding of
immobilized C4BP to the virus (Figure 2A), and conversely, ofFrontiers in Immunology | www.frontiersin.org 5immobilized virus to C4BP (Figure 2B) was observed. As evident
in Figures 2A, B, C4BP bound to H3N2 and H1N1 in a dose-
dependent manner; binding to H3N2 was greater than to H1N1
(Figure 2A) subtype. Recombinant C4BP alpha chain (rC4BP)
(Supplementary Figure 1) was also used to confirm its binding to
the virus. No significant difference in binding efficiency was
observed between the recombinant C4BP and the plasma
purified C4BP (Figures 2C, D).
C4BP Binds HA, NA, and M1 Proteins of
Influenza A Virus
In order to identify the IAV proteins that interact with C4BP,
far-western blot analysis was performed. When SDS-PAGE
separated IAV proteins were probed with C4BP, it revealed
that C4BP interacted with IAV viral proteins Hemagglutinin
(HA) (~70 kDa), Neuraminidase (NA) (~55 kDa) and Matrix
protein 1 (M1) (~25kDa) (Figure 3A). The identities of C4BP
bound IAV glycoproteins were confirmed using separate blots
that were directly probed with anti-HA (Figure 3B), anti-NA
(Figure 3C), anti-M1 (Figure 3D), or anti-NS1 antibodies
(Figure 3E). IAV proteins separated by SDS-PAGE were
probed directly with anti-C4BP antibodies to rule out non-
specific interaction between the antibody and IAV proteins
(Figure 3F). NS1 protein has similar molecular weight to M1,
but the blot with antibodies confirmed M1 as the 25kDa species
involved in binding.
Influenza A Virus Binding Sites Within
C4BP a-Chain Appear to Be Localized
Within CCP4-5 and CCP7-8 Modules
To identify the likely binding site on C4BP for the IAV, an
indirect ELISA was performed using recombinant C4BP a-chain
mutants lacking individual CCP domains. Recombinant C4BP
lacking CCP4, 5, 7, or 8 showed relatively weaker binding to
H1N1 and H3N2 subtypes. The deletion of CCP domain 8
reduced binding by approximately 75% for both subtypes
when compared to full-length C4BP. Deletion of CCP7
resulted in reduced binding for H1N1 (~49%) as well as H3N2
(~62%). The CCP4 and 5 deletion mutants lost ~80% binding
activity for H3N2 and ~60% for H1N1. Approximately 20% loss
of binding for H1N1 was observed in the case of CCP1 and 2
deletants, but the same deletants showed ~80% reduction in
binding to H3N2. The loss of CCP domains 3 and 6 caused a
small increase in binding by approximately 10% for both IAV
subtypes. This indicates that C4BP binds both IAV subtypesTABLE 3 | Forward and reverse primers used for qRT-PCR.
Target Forward primer Reverse primer
18S 5′-ATGGCCGTTC TTAGTTGGTG-3′ 5′-CGCTGAGCCA GTCAGTGTAG-3′
IL-6 5′-GAAAGCAGCA AAGAGGCACT-3′ 5′-TTTCACCAGG CAAGTCTCCT-3′
IL-12 5′-AACTTGCAGC TGAAGCCATT-3′ 5′-GACCTGAACG CAGAATGTCA-3′
TNF-a 5′-AGCCCATGTT GTAGCAAACC-3′ 5′-TGAGGTACAG GCCCTCTGAT-3′
M1 5′AAACATATGTCTGATAAC GAAGGAGAACAGTTCTT-3′ 5′GCTGAATTCTACCT CATGGTCTTCTTGA-3′
RANTES 5′-GCGGGTACCAT GAAGATCTCTG-3′ 5′-GGGTCAGAATC AAGAAACCCTC-3′
IFN-a 5′-TTT CTC CTG CC T GAA GGA CAG-3′ 5′-GCT CAT GAT TTC TGC TCT GAC A-3′January 2021 | Volume 11 | Article 585361
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(Figure 4). However, in the case of the H3N2 subtype, and to a
lesser extent H1N1 subtype, it appears that there is an additional
binding interaction with CCPs 1-2 (Figure 4B). This may be
consistent with greater binding to H3N2. VSV-G pseudo-typedFrontiers in Immunology | www.frontiersin.org 6lentivirus that was used as negative control showed no significant
binding (Figure 4C).
C4BP Inhibits H1N1 Replication
HA, NA, and M1 are essential IAV proteins which have many
functions from viral entry to virion budding, bringing about IAV
infectivity and replication. Therefore, we investigated the effect of
C4BP on cell infection. A549 cells were challenged with either
H1N1 or H3N2 for 6 h that were previously incubated with
C4BP. The efficacy of replication was estimated by comparing
the M1 expression levels of the virions treated with C4BP (10, 20,
or 40 µg/ml) to the cells infected with IAV but, not treated with
C4BP. M1 mRNA levels were downregulated by C4BP in the case
of H1N1 (−4 log10), suggesting that the interaction of C4BP with
H1N1 reduced the replication efficiency of the virus at an early
stage of the replication cycle. However, in the case of A549 cells
challenged with H3N2, M1 mRNA levels were found to be
upregulated (2 log10), suggesting an increase in IAV replication
efficacy. Taken together, these results suggest that C4BP
differentially modulates viral entry, and thus, replication
efficacy among the IAV subtypes (Figure 5).
C4BP Is an Entry Inhibitor for H1N1
As C4BP was found to interact with HA and NA, the IAV
proteins that play an integral role in viral host cell recognition
and entry, lentiviral pseudo-particles were used to study the
entry process independent of other IAV components. The
pseudo-particles expressing the respective IAV coat proteins
with an HIV-Luciferase backbone were used as a safer
alternative to assess the role of C4BP as an entry modulator of
H1N1 and H3N2. This system contains a single packaging
plasmid (psPAX2) encoding genes including Gag, Pol, and Tat.
pHIV-Luciferase was used as a lentiviral transfer plasmid, which
is flanked by long terminal repeat (LTR) sequences and designed
to express the firefly luciferase reporter. Thus, pHIV-Luciferase is
replication-incompetent which contains an additional sequence
deletion in the 3′ LTR leading to viral self-inactivation post-
integration. Purified H1+N1 and H3+N2 pseudo-typed particles
pre-incubated with C4BP (20 mg) were used to infect MDCK
cells. The lentiviral particles not treated with C4BP were used as
controls. A ~56% reduction in luciferase reporter activity was
observed when MDCK cells infected with C4BP-treated H1+N1
pseudo-typed particles were compared to their untreated
counterparts. However, an opposite effect, although not so
dramatic, was observed following C4BP treatment in the case
of H3N2 unmatched pseudo-particles. A ~17% increase in
luciferase activity was observed in the treated samples when
compared to the control (Figure 6). C4BP protein seems to be
acting as an entry inhibitor for H1N1, but a weak facilitator of
infection by H3N2.C4BP Modulates Pro-inflammatory
Cytokine/Chemokine Response
in IAV-Challenged A549 Cells
Pro-inflammatory cytokines and chemokines, such as IL-1, IL-6,
IL-12, IFN-a, and NF-kB transcription factor, are a hallmark ofA
B
FIGURE 1 | Characterization of purified C4BP. (A) SDS-PAGE (12% w/v
acrylamide/bisacrylamide) was loaded with 5 µg of purified C4BP in lane 2, along
with a protein ladder with a range of 250 to 10 kDa (Thermofisher) in lane 1. The
denatured and reduced samples were run for 120 min at 90 V and stained with
Coomassie brilliant blue to reveal protein bands corresponding to the a-chain
(~70kDa) and a faint band corresponding to b-chain of C4BP (~45 kDa).
(B) Immunoreactivity of the purified C4BP was analyzed by western blotting. A
PVDF membrane with 1.25, 2.5, and 5 µg of purified C4BP in lanes 2, 3, and 4,
respectively, along with a protein ladder with a range of 250 to 10 kDa
(Thermofisher) in lane 1 was probed using rabbit-anti-human C4BP polyclonal
antibodies (1:1,000) at room temperature for 1 h, followed by incubation with
secondary goat anti-rabbit IgG HRP-conjugate (1:1,000) for 1 h at room
temperature. Bands corresponding to a-chain (~70 kDa) and the b-chain
(~45 kDa) of the C4BP were observed after developing the color using 3,3′-
diaminobenzidine (DAB) substrate.January 2021 | Volume 11 | Article 585361
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the pro-inflammatory cytokines produced during IAV infection,
A549 cells were challenged with H1N1 and H3N2 viruses
(MOI 1) preincubated with C4BP. qRT-PCR was then carried
out using total RNA from the cells (Figure 7), using cells infected
with IAV that were not treated with C4BP as the control. C4BP
treated H1N1 challenged A549 cells showed lower levels of IFN-
a (-2 log10) at both 2 and 6 h, whereas cells challenged with C4BP
treated H3N2 exhibited higher levels of IFN-a 6 h post-infection
(Figure 7A). IL-12 is essential for the generation of cell-mediated
immunity via the production of IFN-g by helper type 1 T (Th1)
cells, which leads to the elimination of the virus (35). Levels
of IL-12 at 2 h in case of A549 cells challenged with either C4BP
treated H1N1 or H3N2 were not detectable (Figure 7B). At 6 h
in C4BP treated H1N1 challenged cells, IL-12 levels were
downregulated (−2 log10), while in cells challenged with C4BP
treated H3N2 the levels were upregulated (1 log10) (Figure 7B).
As interferon response is triggered by the detection of viral
components within infected cells, and IL-12 induction requires
live viruses, these results are consistent with the previously
observed levels of M1 transcript.
The transcription factor, NF-kB, is a regulator of antiviral
cytokines such as IFN-b, which initiates a strong type I IFN
immune response. IAV induces IFN expression via NF-kB as
viral titer levels are higher in cells treated with an anti-IFN-a/b
receptor antibody and not in dominant-negative IkBaFrontiers in Immunology | www.frontiersin.org 7expressing cells (36). NF-kB mRNA levels at 2 h were slightly
upregulated in C4BP treated H1N1 challenged cells and no
significant change in its levels were observed in cells challenged
with C4BP treated H3N2 (Figure 7C). Cells infected with C4BP
treated H1N1 at 6 h exhibited lower levels of NF-kB (−1 log10),
and no significant changes were observed in C4BP treated H3N2
infected cells (Figure 7C). The lower levels of NF-kB can be
attributed to either low viral titer in the case of H1N1 or the IAV
non-structural protein NS1 which acts as a major suppressor of
NF-kB activation (37).
Increased levels of IL-6, TNF-a, and IFN-g, have been
detected in individuals infected with acquired acute as well as
severe seasonal IAV-infected patients (38, 39). Production of
TNF-a during IAV infection correlates with morbidity and
mortality rates in IAV infected humans and macaques (40, 41).
Six hours post-infection, TNF-a mRNA levels were upregulated
(2 log10) in A549 cells infected with C4BP treated H1N1 or
H3N2, while at the earlier 2-h time point a slight upregulation
was observed (Figure 7D).
RANTES is a C-C chemokine and a potent chemoattractant
for monocytes, T lymphocytes, basophils, and eosinophils. IAV,
via its HA, can induce RANTES expression, probably through
the activation of NF-kB, and cause airway hypersensitivity by
inducing the continuous infiltration of eosinophils (42). C4BP
treated H1N1 challenged A549 cells exhibited lower levels of
RANTES expression (−2 log10) at 2 h compared to the control;A B
DC
FIGURE 2 | Binding interaction of immobilized C4BP to IAV subtypes (A), and immobilized IAV subtypes to C4BP (B). Microtiter wells were coated with a varied
concentration of C4BP (5, 2.5, and 1.25 µg/ml) protein and incubated with constant volume of viruses (1,000 PFU/ml). Bound C4BP-IAV was probed with
monoclonal anti-influenza virus H1 and polyclonal anti-influenza virus H3 antibody (1:5,000). Another ELISA was performed by coating a constant concentration of
IAV subtypes (1,000 PFU/ml) and incubated with a varied concentration of C4BP protein (5, 2.5, and 1.25 µg/ml). IAV-C4BP interaction was detected using
polyclonal rabbit anti-human C4BP antibodies and anti-rabbit IgG-HRP-conjugated antibody (1:5,000). A validation ELISA to show the detection of H1N1 (C) and
H3N2 (D) binding to a recombinant C4BP (rC4BP) and plasma purified C4BP. Microtiter wells were coated with immobilized rC4BP and the plasma purified C4BP
(5 µg/ml), and incubated with H1N1 or H3N2 (1,000 PFU/ml). The binding between immobilized proteins and IAV subtypes were detected using monoclonal anti-
influenza virus H1 and polyclonal anti-influenza virus H3 antibody (1:5,000). VSV-G pseudo-typed lentiviral particles were used as a negative control; no significant
binding was observed. The data were expressed as the mean of three independent experiments done in triplicates ± SEM.January 2021 | Volume 11 | Article 585361
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H3N2 (Figure 7E). RANTES expression (2 log10) was
upregulated at 6 h in the case of both subtypes (Figure 7E).
Enhanced levels of IL-6 have been observed in the serum and
lungs of IAV infected patients. It is unknown whether IL-6 in
IAV infected patients contributes to lung pathology caused by
the viral infection or if increased levels of IL-6 contribute to a
protective mechanism against IAV (39, 43). Levels of IL-6 at 2 h
in C4BP treated A549 cells challenged with either virus were not
detectable (Figure 7F). At 6 h in C4BP treated H3N2 infected
cells, IL-6 levels (2 log10) were upregulated; in cells challenged
C4BP treated H1N1 the IL-6 levels (0.5 log10) were also
upregulated (Figure 7F). Studies also suggest that signals
mediated by IL-6 are crucial for survival against a non-lethal
dose of H1N1 infection, and IL-6/IL-6R deletion inhibits H1N1
clearance together with reduced neutrophils levels in the lungs of
infected mice (44).DISCUSSION
The Influenza virus, an upper respiratory tract pathogen, is
known to have caused some of the deadliest pandemics in
history. To develop better IAV treatment strategies and
mitigate the risk of the current viral strains evolving to a more
pathogenic one by reassorting among themselves, a better
understanding of the immune mechanisms against IAV is
required. Here, we examined the complement-independent
role of C4BP, a complement regulator, against IAV. ManyFrontiers in Immunology | www.frontiersin.org 8pathogens such as adenoviruses, Yersinia pestis, and Aspergillus
spp. are known to bind C4BP to promote survival and
proliferation (15). C4BP is a major fluid phase inhibitor of the
classical and the lectin pathways, making it a prime target for the
exploitation by pathogens to circumvent the host’s potent
humoral immune system, such as complement. In this study,
we sought to understand the interactions between C4BP and IAV
in a serum-free system and explore any complement-
independent functions of C4BP with respect to IAV.
We first established protein-protein interactions between
C4BP and IAV subtypes. C4BP a chain was found to bind
IAV subtypes (Figures 2A, B), and H3N2 was found to bind
C4BP with higher affinty than H1N1. This interaction with the a
chain of C4BP was further confirmed using rC4BP (Figures 2C,
D). The C4BP a chain was found to interact with viral envelope
protein HA, NA, and surprisingly, M1 (Figure 3). As the M1
protein lies beneath the lipid layer, the interaction likely occurs
by the abundantly present non-packaged M1 that are released
from ravaged cells during late stages of infection to help increase
the odds of survival of the virus (45).
It was also possible that C4BP interacted with IAV NS1, but
the signal was masked by the interaction of C4BP with M1 due to
the low concentrations of NS1 when compared to M1, as
proteins share similar molecular weights. Avirutnan et al. have
shown that Flavivirus NS1 restricted the activation of classical
and lectin pathways by binding to C4BP, thereby enabling the
virus to evade C4b mediated lysis (5). Since both NS1 proteins
share independent immunoregulatory functions, the binding of
Influenza NS1 with C4BP was also considered. Far western blotA B
D E F
C
FIGURE 3 | Far Western blot analysis showing C4BP binding to H1N1 and H3N2 proteins. PVDF membrane containing H1N1 and H3N2 virus proteins, separated
by SDS-PAGE was blocked with 5% w/v skimmed milk and incubated with 5 µg/ml of C4BP (A) or without C4BP (F) followed by washing steps. The membrane
was probed with rabbit-anti-human C4BP polyclonal antibodies (1:1,000) at room temperature for 1 h, followed by washing and incubation with secondary goat anti-
rabbit IgG HRP-conjugate (1:1,000) for 1 h at room temperature. Bands corresponding to Hemagglutinin (HA) (~70 kDa), Neuraminidase (NA) (~55 kDa), and Matrix
protein 1 (M1) (25 kDa) in the case of both H1N1 and H3N2 subtypes were revealed after developing colour using 3,3′-diaminobenzidine. The identities of C4BP
bound IAV glycoproteins were confirmed using separate blots that were directly probed with anti-HA (B), anti-NA (C), anti-M1 (D), or anti-NS1 (E) antibodies.January 2021 | Volume 11 | Article 585361
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M1 that C4BP bound to at ~26 kDa; probing with monoclonal
Anti-IAV NS1did not reveal any bands corresponding to NS1
protein. Furthermore, multiple sequence alignment and identity-Frontiers in Immunology | www.frontiersin.org 9similarity analysis on IAV NS1 [(Accession #: P03495; P03496)
and Flavivirus NS1 (Accession #: Q6J3P1 Residues: 779-1130)
(P29991) Residues: 776-1127; P06935 (Residues: 788-1139)]
performed using Clustal Omega and Sequence Manipulation
Suite (Data not shown) revealed IAV NS1 and Flavivirus NS1
have sequence similarity scores that are lower than 25%.
Use of deletion mutants lacking specific CCP domains of
C4BP revealed that H1N1 and H3N2 subtypes interacted via
multiple CCP domains, CCP1-2, CCP4-5, and CCP7-8 of the
C4BP a-chain. It is known that the Flavivirus NS1-C4BP binding
is mediated through CCP2-5 and 8. Since CCP8 is near to the C-
terminal oligomerization domain, its loss could affect the
conformational structure of C4BP, which can affect the
accessibility of NS1 to CCP2-5 (5). Similarly, the deletion of
CCP8 reduced IAV-C4BP binding by ~75% (Figure 4). Deletion
of CCP4-5 inhibited binding by ~79% to H3N2 and ~67% to
H1N1 (Figure 4). C4BP binds C4b through CCP1-3, with
domains 2 and 3 being the most critical for the interaction
(10). The loss of CCP1-2 reduced binding efficiency of H3N2
and, to a lesser extent, of H1N1 to C4BP (~80% for H3N2 and
~20% for H1N1) (Figure 4). It is possible that the IAV virus, like
other pathogens such as S. pyogenes, Neisseria gonorrhoeae,
Bordetella pertussis, Moraxella catarrhalis, Borrelia recurrentis,
Candida albicans, and Hemophilus influenzae, is exploiting the
natural binding site for C4b (8). This preference for the site can
be attributed to its immutability, accessibility and the fact that
the region may contain intrinsic properties which favor ligand
binding (46). Furthermore, this increased binding affinity
between CCP1-2 and H3N2 may explain the difference in the
binding efficiency of C4BP to H3N2 when compared to H1N1, as
seen in Figure 2. As plasma purified C4BP is a glycoprotein, and
therefore, is likely to contain N-glycosides that are sialylated; it is
possible for sialic acid residues to bind to HA/NA. C4BP
[UniProtKB - P04003 (C4BPA_HUMAN)] has N-linked
glycosylation only in CCP3 and CCP8 and so sialic acid is
likely to occur only at these sites. Our results do not implicate
CCP3 in binding, but it remains a possibility that CCP8 binding
could involve sialic acid.
It is likely that C4BP is regulating viral replication levels by
modulating viral entry. To establish this, second-generation
matched and unmatched lentiviral vectors, pseudo-typed for
H1+N1 and H3+N2, respectively, were generated. This system
was selected as a safe alternative method to mimic the structure
and surfaces of IAV and prove that C4BP acts as an entry
inhibitor in cells transduced with pseudo-typed IAV particles
that are restricted to only one replicative cycle. A luciferase
reporter assay revealed a 56% reduction in H1N1 pseudo-typed
viruses treated with C4BP that entered the cells, corresponding
with the 4-fold decrease observed in the M1 mRNA levels of
H1N1 infected cells (Figures 5 and 6), while a slight increase
(~17%) was observed in case of the H3N2 pseudo-particles
(Figure 6), consistent with M1 levels. This suggests that C4BP
acts as an entry inhibitor for H1N1 while it has limited restrictive
potential against H3N2.
Recently, factor H, the principal regulator of the alternative
pathway, and vaccinia virus complement control protein (VCP),A
B
C
FIGURE 4 | C4BP interacts with IAV through multiple CCP domains. ELISA
showing binding of C4BP CCP deletion mutants to (A) H1N1, (B) H3N2 and
(C) VSV-G: microtiter wells were coated with 5 µg/ml of the mutant C4BP
protein (as described in Table 1). 1000 PFU/ml of H1N1 or H3N2 virus was
added to all the wells. After incubation and washing steps, the bound virus
was measured with either monoclonal anti-influenza virus H1, polyclonal anti-
influenza virus H3 or polyclonal anti-VSV-G antibody. Results are normalised
against full length C4BP a chain. The data were expressed as the mean of
three independent experiments done in triplicates ± SEM. Significance was
determined using the two-way ANOVA test (*p < 0.05, **p < 0.01, and
****p < 0.0001) (n = 3).January 2021 | Volume 11 | Article 585361
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manner similar to C4BP (32). MDCK cells infected with H1+
N1pseudo-typed lentiviral particles resulted in approximately
25% and 45% reduction in luciferase activity after treatment with
factor H or VCP, respectively. However, a 50% increase in
luciferase activity in MDCK infected with H3+N2 pseudo-
typed lentiviral particles was observed when treated with factor
H, and 30% when treated with VCP was observed. Hence, the
treatment with these proteins resulted in restriction of IAV entry
and replication by 4-fold for the H1N1 subtype, while promoting
entry and replication by 2-fold for H3N2. Thus, using lentiviral
vectors, pseudo-typed for H1+N1 and H3+N2, Murugaiah et al.
demonstrated the ability of Factor H and VCP to modulate IAV
entry, in a subtype dependent manner, similar to C4BP (32).
As seen in the case of C4BP, Murugaiah et al. also suggested
that FH and VCP to accomplished the subtype dependent entry
modulation via interaction with HA, NA, and M1. Additionally,
FH and VCP were also shown to trigger an anti-inflammatory
response in case of H1N1 subtype while leading to pro
inflammatory response in H3N2 subtype. The inflammatory
response was also modulated in a subtype-specific manner.
Transcriptional levels of IFN-a, TNF-a, IL-12, IL-6, and IFN-
a were upregulated, while RANTES was downregulated
following factor H treatment for the H1N1 subtype at 6 h
post-infection. In the case of the H3N2 subtype, mRNA levels
of these pro-inflammatory cytokines were enhanced (32). The
findings of this study highlight a possible common mechanism
that is used by C4BP, VCP, and Factor H that contain CCP
domains in modulating the entry of IAV subtypes. The heparin-Frontiers in Immunology | www.frontiersin.org 10binding sites on Factor H (surface of CCP7, CCP13 and CCP20)
and VCP (tip of module 4) are also found on C4BP a chain (CCP
domains 1-2) (9, 47). These sites may provide a possible
explanation for the effect observed on viral entry modulation
among the IAV subtypes. In this study, we have shown that IAV
subtypes bind C4BP via the heparin-binding site containing CCP
domain 1-2 (Figure 4). We suspect the overlapping heparin-
binding and IAV binding sites may contribute to the variation
observed between the subtypes. C4BP has been shown to
enhance adenovirus uptake in hepatocytes by providing a
bridge between the adenovirus fiber knob domain and cell
surface Heparan Sulfate Proteoglycans (HSP) (16); we
speculate that the increased efficiency observed between the
binding of C4BP’s CCP1-2 domain and H3N2 subtype
compared to H1N1 subtype may contribute to the increased
H3N2 virion entry in a similar fashion. The similarity of the
results between the interaction of C4BP, Factor H, and VCP to
IAV subtypes further support this idea and requires further study
by treating cells with heparinase prior to C4BP treatment and
infection to confirm whether the variation between the subtypes
may be modulated by the interaction with HSP.
Another explanation for differences in outcome in spite of
C4BP binding both viruses may arise from the local variations
found between H1 and H3 or N1 and N2 or the variation in
C4BP binding sites to HA or NA. HA and NA are classified into
two groups regardless of their serotype identification. In case of
NA, N1 belongs to group 1, which lacks an additional cavity next
to the active site that is created by the movement of “150 loop”
during conformational changes caused by the binding of
substrate to the active site (48). N2 belongs to group 2 whichFIGURE 6 | C4BP modulates viral entry in a strain-dependent manner.
Luciferase reporter activity of C4BP treated MDCK cells infected with
matched H1+N1 and unmatched H3+N2 lentiviral pseudo-particles. H1N1
particles exhibited a 55% decrease in viral entry compared to controls, while
a 17% increase in viral entry in case of H3N2 was observed. Results are
normalized against cells infected with the particles not treated with C4BP.
Significance was determined using the unpaired one-way ANOVA test
(****p < 0.0001) (n = 3).FIGURE 5 | C4BP restricts replication of H1N1 and promotes replication of
H3N2 in target human A549 cells. M1 expression of both H1N1 and H3N2
IAV after infection of A549 cells for 6 h was measured by qRT-PCR. A549
cells were challenged either with H1N1 or H3N2 (MOI 1) that were incubated
with varying concentration of C4BP (10, 20, and 40 µg/ml). Cell pellets were
harvested at 6 h to analyze the M1 expression of IAV. Cells were lysed, and
RNA extracted was converted into cDNA. Infection was measured via qRT-
PCR using M1 primers; 18S rRNA was used as an endogenous control. The
relative expression (RQ) was calculated by using cells infected with respective
viruses that were not treated with C4BP as the calibrator. The RQ value was
calculated using the formula: RQ = 2−DDCt. Assays were conducted in
triplicates, and error bars represent ± SEM. Significance was determined
using the two-way ANOVA test (****p < 0.0001) (n = 3).January 2021 | Volume 11 | Article 585361
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functions in virus internalization by enabling movement of the
virus across the cell surface from an endocytosis inactive site on
the cell to an active site, thereby increasing the efficiency of viral
uptake (49). NA has also been shown to boost HA-dependent
influenza virus fusion and infectivity by employing a cell-cell
fusion assay and an HIV-based pseudo-typed infectivity assay
(50). It is possible that the structural differences between N1 and
N2 after binding to C4BP may affect their role in virus
internalization. Similarly, HA can also be classified into two
groups based on structural characteristics, with H1 in group 1
and H2 in group 2 (51). Hence, localized variations found on HA
could influence potential binding pocket for C4BP on the HA, as
seen in the case of Stachyflin (52). These structural variations in
HA and NA may also explain the increased binding observed
between C4BP and H3N2. It will be important to investigate the
effect of differential interplay between HA and NA of H1N1 and
H3N2 viruses on the infection modulation activity of C4BP.
Additionally, the variation in binding efficiency of CCP1-2
between H3N2 and H1N1 suggests that the binding while
overlapping, does not occur at identical sites, as seen in the
case of C4BP binding to C4b, S. pyogenes, or B. pertussis (46, 53,
54). It may be possible that this variation and difference in
binding efficiency further affects downstream interactions such
as C4BP or IAV’s interaction with other receptors or proteins
that may affect viral entry (55, 56).
During an IAV infection, elevated levels of cytokines and
chemokines are observed, including IL-6, TNF-a, IFNs, IL-1b,
RANTES, IL-8, MIP1b, and MCP1 (57–60). Inflammation is a
critical part of the immune response against IAV infection.
Cytokines such as TNF-a, IL-12, and IFNs are known to play
a significant role to cellular inflammation. To study the
modulation of these cytokines by C4BP, we performed qPCR
on A549 cells infected with C4BP treated H1N1 or H3N2
(treated) and standardized them against A549 cell infectedFrontiers in Immunology | www.frontiersin.org 11under similar conditions using viruses that were not treated
with C4BP (untreated) to obtain the relative expression levels of
the cytokines. Type I interferons like IFN a and IFN b are critical
mediators of virus clearance during an IAV infection. Six hours
post-infection in the treated cells, IFN-a mRNA levels were
downregulated in case of H1N1 (−2 log10) and upregulated (2.5
log10) in case of C4BP treated H3N2 infected cells (Figure 7A).
This suggests the formation of an antiviral state in the infected
and its neighbouring cells, thereby reducing viral replication and
disease severity (61, 62). The elevated levels of IFN-a mRNA
observed in A549 cells challenged with the C4BP treated H3N2
subtype suggest that C4BP is being protective by promoting a
type 1 interferon response despite not acting as an entry inhibitor
for H3N2. The cytokine mRNA expression was downregulated
(−2 log10) in the case of both viruses 2 h post-infection and can
be attributed to the low viral load present at the time
(Figure 7A).
We found that IL-12 mRNA levels were too low to be detected
2 h post-infection, but the relative mRNA upregulation (1 log10)
was observed 6 h post-infection in cells infected with C4BP
treated H3N2 compared to its control (Figure 7B). This clearly
indicates the presence of a response that would culminate in the
prevention of viral replication, activation of cytotoxic T
lymphocytes and early NK cell-dependent gamma interferon
production (63). The entry inhibitory effect of C4BP on H1N1
subtype, and the subsequent lower viral replication and load is
further demonstrated by the downregulation (−2 log10) of IL-12
mRNA in the C4BP treated H1N1-infected cells compared to
their untreated counterparts 6 h post-infection (Figure 7B).
The TNF-a–NF-kB axis leads to the expression of a number
of inflammatory genes, induction of apoptosis and production of
ROS (64–66). NF-kB mRNA in cells infected with C4BP treated
H1N1, 2 h post-infection was found to be relatively upregulated
(~0.3 log10), while a downregulation (~−0.7 log10) of the mRNA
was recorded 6 h post-infection when compared to the untreatedA B
D E F
C
FIGURE 7 | Cytokine modulation by C4BP of IAV infected A549 cells. H1N1 or H3N2 incubated with 10µg/ml of C4BP was used to infect A549 cells. Cell pellets
were harvested at 2 h and 6 h to analyse the expression of cytokines and chemokines. Cells were lysed, and purified RNA was converted into cDNA. The expression
levels of cytokines IFN-a (A), IL-12 (B), NF-kB (C), TNF-a (D), IL-6 (F) and chemokine RANTES (E) were measured using qRT-PCR, and the data were normalised
via 18S rRNA expression as a control. The relative expression (RQ) was calculated by using cells infected with respective viruses not treated with C4BP as the
calibrator. The RQ value was calculated using the formula: RQ = 2−DDCt. Assays were conducted in triplicates, and error bars represent ± SEM. Significance was
determined using the two-way ANOVA test (**p < 0.01, and ****p < 0.0001) (n = 3).January 2021 | Volume 11 | Article 585361
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H3N2, we found an upregulation of NF-kB mRNA 6 h post-
infection, while no significant modulation was observed 2 h post-
infection (Figure 7C). This variation in NF-kB mRNA levels 6 h
post-infection among the IAV subtype further confirms the
subtype dependent entry inhibitory action of C4BP on IAV.
When compared to their untreated counterparts, the cells
infected with either C4BP treated H1N1 or H3N2 were found
to upregulate TNF-a mRNA (Figure 7D), indicating a robust
inflammatory response at both 2 h (0.2 log10) and 6 h (~1.7 log10)
post-infection (67, 68).
RANTES is an important chemokine that been associated
with extensive inflammation of the lung in cases of avian
Influenza and increased mortality in IAV challenged CCR5−/−
mice (69). RANTES mRNA expression levels in treated H1N1
challenged cells 2 h post-infection, was found to be significantly
downregulated (−2 log10) while it was not detected in case of
H3N2 (Figure 7E). RANTES mRNA levels in cells were
upregulated observed in case of both C4BP treated viral
subtypes (2 log10) 6 h post-infection, suggesting an active
recruitment of leukocytes to the inflammatory sites (Figure 7E).
Another cytokine associated with both pro-inflammatory and
anti-inflammatory effects is IL-6 (70). Its synthesis is upregulated
during infection to simulate the adaptive immune response by
inducingdifferentiationof activatedBcells andCD4+Tcells (71). In
the case of IAV infection, IL-6 seemed to have a protective role in
murine models, promoting viral clearance and limiting
inflammation (72). IL-6 mRNA levels at 6 h was found to be
upregulated in case of H1N1 (0.5 log10) and H3N2 (1.5 log10)
(Figure 7F) after C4BP treatment. These results suggest that C4BP
may entice differential adaptive immune response.
It would be interesting to study if C4BP can also bind avian
IAV. Another area to explore further would be investigate in
humanized murine models to understand better the impact of
C4BP-IAV interaction in the microenvironment of the
respiratory system, and elucidation of mechanism resulting in
the subtype-dependent entry modulation of IAV by C4BP.
In conclusion, we show that C4BP differentially regulates the
efficacy of Influenza A virus replication in a subtype-dependent
manner by modulating their entry into the cells, and provide an
interesting candidate to be developed into a HA and NA-based
inhibitor against IAV infections. Recombinant forms of CCP4+5
and/or CCP7+8 are likely to be excellent vehicles for therapeutic
development against IAV pandemic H1N1 subtype.DATA AVAILABILITY STATEMENT
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